Download FREE Report Sample
Download Free sampleThe global Hydroxycarbamide market was valued at 210.06 Million USD in 2021 and will grow with a CAGR of 5.86% from 2021 to 2027, based on Research newly published report.
The prime objective of Hydroxycarbamide Market is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, Hydroxycarbamide Market covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA. The classification of Hydroxycarbamide includes capsule and tablet, and the proportion of capsule in 2016 is about 63%, and the proportion is in decreasing trend from 2012 to 2016. Hydroxycarbamide is widely used for sickle cell disease, cancer and other disease. The most proportion of Hydroxycarbamide is used for sickle cell disease, and the proportion in 2016 is 45%. Asia Pacific is the largest supplier of Hydroxycarbamide, with a production market share nearly 59% in 2016. Middle East and Africa is the largest consumption place, with a consumption market share nearly 36% in 2016. Following Middle East and Africa, Asia Pacific is the second largest consumption place with the consumption market share of 20%. Market competition is not intense. Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
By Market Verdors:
By Types:
By Applications:
Key Indicators Analysed
Key Reasons to Purchase
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy